Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(50.0%)
Phase 1
2(33.3%)
Phase 2
1(16.7%)
6Total
Phase 3(3)
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02517788Phase 1Completed

Phase I BP Interferon (IFN) Beta-004

Role: collaborator

NCT02515695Phase 1Completed

Phase I BP Interferon (IFN) Beta-001

Role: collaborator

NCT00294619Phase 3Completed

Treatment of Adults With Growth Hormone Deficiency

Role: collaborator

NCT00596037Phase 3Completed

Treatment of Adults With Growth Hormone Deficiency

Role: collaborator

NCT00271518Phase 3Unknown

Treatment of Children With Insufficient Secretion of Growth Hormone

Role: collaborator

NCT00600808Phase 2Completed

Sustained Release Formulation of Somatropin (rDNA Origin)for Injection

Role: lead

All 6 trials loaded